Method for treatment of multiple sclerosis

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

Reexamination Certificate

active

07465715

ABSTRACT:
Individuals suffering from multiple sclerosis may be treated by administration of an A3 adenosine receptor agonist (A3RAg), such as APNEA, AB-MECA, IB-MECA or Cl-IB-MECA. The A3RAg is preferably administered orally with a pharmaceutically acceptable carrier.

REFERENCES:
patent: 5506214 (1996-04-01), Beutler
patent: 5773423 (1998-06-01), Jacobson et al.
patent: 6117878 (2000-09-01), Linden
patent: 6303619 (2001-10-01), Linden
patent: 6762170 (2004-07-01), Chan et al.
patent: 2002/0094974 (2002-07-01), Castelhano et al.
patent: WO 95/11681 (1995-05-01), None
patent: WO 97/33879 (1997-09-01), None
patent: WO 2004/058791 (2004-07-01), None
Gold et al., “Animal Models for Autoimmune Demyelinating Disorders of the Nervous System,” Molecular Medicine Today, 6, 88-91 (Feb. 2000).
Link et al., “Rat Models as Tool to Develop New Immunotherapies,” Immunological Reviews, 184, 117-128 (2001).
Mix et al., “Gene-Expression Profiling of Experimental Autoimmune Encephalitis,” Neurochemical Research, 27(10), 1157-1163 (Oct. 2002).
Siddiqi, S.M. et al., “Search for New Purine- and Ribose-Modified Adenosine Analogues as Selective Agonists and Antagonists at Adenosine Receptors”, J. Med. Chem, (1995), vol. 38, pp. 1174-1188.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Method for treatment of multiple sclerosis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for treatment of multiple sclerosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treatment of multiple sclerosis will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4035963

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.